Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537223 | 0.88 | ERN1 (0.62) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL14727969 | 0.87 | VCAM1 (0.58) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL11965649 | 0.87 | VCAM1 (0.58) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| Dimethylamine SCHEMBL9479039 | 0.84 | VCAM1 (0.56) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL14723109 | 0.84 | VCAM1 (0.63) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL14723107 | 0.84 | VCAM1 (0.63) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL7072145 | 0.84 | ERN1 (0.46) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL3598047 | 0.84 | KMT2A (0.61) | ERN1ALDH1A1HPGDNPSR1KDM4E | |
| SCHEMBL15894151 | 0.84 | VCAM1 (0.63) | ERN1VCAM1ALDH1A1HPGDNPSR1 | |
| SCHEMBL19295317 | 0.84 | ALDH1A1 (0.49) | ERN1VCAM1ALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822065-B1 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-11-21 | — | — | US | claimed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4620470-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4617272-A1 | FUSED BICYCLIC COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025126115-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-19 | — | — | WO | disclosed |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| US-12312363-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-6414008-B1 | CYNAO- OR AMIDINE-SUBSTITUTED BENZIMIDAZOLES, BENOTHIAZOLES, OR BENZOXAZOLES; 2-(N-(4-AMIDINOPHENYL)AMINOMETHYL)BENZOTHIAZOLES; 2-((4-CYANOPHENYL)OXYMETHYL)IMIDAZOL(4,5-B)PYRIDINES; ANTITHROMBOTICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | disclosed |
| CN-1230196-A | Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. | THOMAE GMBH DR K (DE) | 1999-09-29 | — | — | CN | disclosed |
| EP-0927192-A1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-07-07 | — | — | EP | disclosed |
| US-5840895-A | INTERMEDIATES FOR ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-11-24 | — | — | US | disclosed |
| WO-1998011128-A1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1998-03-19 | — | — | WO | disclosed |
| US-5686442-A | ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0686636-A1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | ERN1 159/4885VCAM1 3876/4885ALDH1A1 4348/4885 |
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | ERN1 1389/4885VCAM1 2504/4885ALDH1A1 3042/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | ERN1 313/4885VCAM1 4298/4885ALDH1A1 3721/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | ERN1 349/4885VCAM1 1850/4885ALDH1A1 3564/4885 |
| US-12312363-B2 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | TP53, MDM2, FOXM1 | ERN1 3243/4885VCAM1 3227/4885ALDH1A1 1055/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | ERN1 2546/4885VCAM1 1951/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.